Guangdong Jiaying Pharmaceutical Co Ltd (SHE:002198) — Market Cap & Net Worth
Market Cap & Net Worth: Guangdong Jiaying Pharmaceutical Co Ltd (002198)
Guangdong Jiaying Pharmaceutical Co Ltd (SHE:002198) has a market capitalization of $433.71 Million (CN¥2.96 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #13296 globally and #4192 in its home market, demonstrating a -23.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangdong Jiaying Pharmaceutical Co Ltd's stock price CN¥5.84 by its total outstanding shares 507509848 (507.51 Million). Analyse Guangdong Jiaying Pharmaceutical Co Ltd (002198) cash conversion ratio to see how efficiently the company converts income to cash.
Guangdong Jiaying Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Guangdong Jiaying Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $804.18 Million to $433.71 Million (-3.51% CAGR).
Guangdong Jiaying Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangdong Jiaying Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.45x
Guangdong Jiaying Pharmaceutical Co Ltd's market cap is 1.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
26.37x
Guangdong Jiaying Pharmaceutical Co Ltd's market cap is 26.37 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $804.18 Million | $475.81 Million | $66.35 Million | 1.69x | 12.12x |
| 2016 | $993.83 Million | $449.95 Million | $55.17 Million | 2.21x | 18.01x |
| 2017 | $906.27 Million | $468.08 Million | -$214.76 Million | 1.94x | N/A |
| 2018 | $375.34 Million | $536.98 Million | $35.88 Million | 0.70x | 10.46x |
| 2019 | $398.93 Million | $500.50 Million | -$122.18 Million | 0.80x | N/A |
| 2020 | $330.36 Million | $544.73 Million | $19.84 Million | 0.61x | 16.65x |
| 2021 | $581.08 Million | $574.71 Million | $1.48 Million | 1.01x | 393.34x |
| 2022 | $480.79 Million | $659.20 Million | $43.93 Million | 0.73x | 10.94x |
| 2023 | $536.84 Million | $533.23 Million | $34.32 Million | 1.01x | 15.64x |
| 2024 | $543.62 Million | $376.17 Million | $20.61 Million | 1.45x | 26.37x |
Competitor Companies of 002198 by Market Capitalization
Companies near Guangdong Jiaying Pharmaceutical Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Guangdong Jiaying Pharmaceutical Co Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $862.20 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #23 globally with a market cap of $547.37 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #37 globally with a market cap of $365.30 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $862.20 Billion | $963.33 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #23 | Johnson & Johnson | NYSE:JNJ | $547.37 Billion | $227.19 |
| #37 | AbbVie Inc | NYSE:ABBV | $365.30 Billion | $206.60 |
Guangdong Jiaying Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guangdong Jiaying Pharmaceutical Co Ltd's market cap moved from $804.18 Million to $ 433.71 Million, with a yearly change of -3.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥433.71 Million | -16.93% |
| 2025 | CN¥522.08 Million | -3.96% |
| 2024 | CN¥543.62 Million | +1.26% |
| 2023 | CN¥536.84 Million | +11.66% |
| 2022 | CN¥480.79 Million | -17.26% |
| 2021 | CN¥581.08 Million | +75.89% |
| 2020 | CN¥330.36 Million | -17.19% |
| 2019 | CN¥398.93 Million | +6.29% |
| 2018 | CN¥375.34 Million | -58.58% |
| 2017 | CN¥906.27 Million | -8.81% |
| 2016 | CN¥993.83 Million | +23.58% |
| 2015 | CN¥804.18 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Guangdong Jiaying Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $433.71 Million USD |
| MoneyControl | $433.71 Million USD |
| MarketWatch | $433.71 Million USD |
| marketcap.company | $433.71 Million USD |
| Reuters | $433.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangdong Jiaying Pharmaceutical Co Ltd
Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines in Mainland China. The company offers medicines primarily for the treatment of throat, cold, orthopedics, rheumatism, gynecology, heat-clearing, tonic, and gastrointestinal diseases. It also provides Shuangliao Houfeng powder, Chongganling tablets, Jiegu Qili tablet… Read more